The expression of TSSC3 and its prognostic value in patients with osteosarcoma

Osteosarcoma is one of the most common primary bone tumors in children and adolescents, typically presenting with poor prognosis. Recent studies have found that TSSC3 had a potential capability in suppressing the tumor development in osteosarcoma. Our purpose was to explore the role of TSSC3 in the clinical outcome of osteosarcoma patients. Firstly, we detected the expression of TSSC3 at mRNA level by quantitative real-time polymerase chain reaction (qRT-PCR). The result demonstrated that TSSC3 expression was lower in osteosarcoma patients than in healthy controls (P < 0.05). Then, the relationship between TSSC3 and clinicopathological characteristics was analyzed by chi-square test which manifested that WHO grade, metastasis, and recurrence were vital influential factors on the expression of TSSC3 (P < 0.05). We also estimated the association between TSSC3 and overall survival of osteosarcoma patients by Kaplan–Meier analysis as well as assessed the prognostic value of TSSC3 and clinicopathological characteristics through cox regression analysis. Patients with high TSSC3 expression were proved to live longer than those with low TSSC3 expression (log rank test, P < 0.05). TSSC3 expression (P = 0.032, HR = 0.405, 95%CI = 0.177–0.926) and metastasis (P = 0.010, HR = 2.849, 95%CI = 1.291–6.287) were considered to be independent prognostic factors in osteosarcoma. Taken together, our findings provided preliminary evidence that the TSSC3 was a prognostic marker in osteosarcoma and this might be useful for the therapy of osteosarcoma.     

The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma

ObjectiveDysregulation of miRNA is always associated with cancer development and progression. Aberrant expression of miR-217 has been found in some types of cancer. However, its expression and function in osteosarcoma remain unclear. The aim of this study was to explore the effects of miR-217 in osteosarcoma tumorigenesis and development.MethodsThe expression level of miR-217 was quantified by real-time RT-PCR in human osteosarcoma cell lines and tissues. MTT, flow cytometric, transwell invasion and migration assays, and tumorigenicity in vivo were adopted to observe the effects of miR-217 on MG-63 cell phenotypes.ResultsMiR-217 was significantly downregulated in osteosarcoma cell lines and clinical specimens. Decreased miR-217 expression was significantly associated with large tumor size, positive distant metastasis, and advanced clinical stage. Low miR-217 expression in osteosarcoma was an independent predictor of poor survival. Overexpression of miR-217 can inhibit the proliferation, invasion, migration and promoted apoptosis of MG-63 cells in vitro and in vivo.ConclusionsThese findings indicate that miR-217 may act as a tumor suppressor in osteosarcoma and would serve as a novel therapeutic agent for miRNA-based therapy.     

免疫性血小板减少性紫癜患者单个核细胞中microRNA-30a表达增高及其意义

目的 探讨microRNA-30a是否参与了免疫性血小板减少性紫癜（ITP）的发病机制.方法 采用实时荧光定量逆转录-聚合酶链反应（FQ-RT-PCR）技术检测38例ITP患者及35例健康者外周血单个核细胞（PBMC）中microRNA-30a和Lyn mRNA的相对表达量,并进行统计分析.结果 ITP患者外周血PBMC中microRNA-30a表达较健康对照组明显增高（P〈0.01）,且与血小板计数呈负相关（r2=0.42,P〈0.05）;ITP患者外周血PBMC中Lyn mRNA表达较健康对照组明显降低（P〈0.01）,且与microRNA-30a呈负相关（r2=0.33,P〈0.01）.结论 microRNA-30a可能通过Lyn参与了ITP的发病机制.     

浅表性骨肉瘤临床病理分析及其微血管密度研究

目的分析浅表性骨肉瘤（OS）的临床、影像学及病理学特征,以CD105标记微血管密度（MVD）探讨与临床病理因素的关系,提高对浅表性OS诊断、鉴别诊断水平和生物学行为评估。方法回顾性分析2006年1月至2012年12月经手术病理证实的11例浅表性OS临床、影像学及病理资料,并进行随访;应用免疫组化SP法检测11例浅表性OS中CD105的表达及MVD,并与18例正常骨组织、29例普通OS对照,分析CD105在浅表性OS中的表达及CD105-MVD与临床病理因素的关系。结果 （1）11例浅表性OS中,骨旁OS 7例（1例双肺胸膜下转移）,骨膜OS 3例,高级别表面OS 1例;年龄16∽68岁,平均26岁;7例股骨远端后面,胫骨近端3例,肱骨远端1例。（2）影像学显示7例呈均一致密的骨性肿块,4例围绕骨表面生长,肿瘤与骨皮质间形成1∽2 mm透亮间隙;CT扫描7例示肿瘤呈高密度肿块,3例骨皮质不完整,肿块内可见低密度间隔,邻近骨皮质增厚,无骨质破坏,1例见骨膜反应,11例均无Codman三角,未侵犯骨髓腔;诊断准确率DR为81.8%（9/11）,CT为54.5%（6/11）,MRI为63.6%（7/11）,3种影像学检查方法结合准确率为90.9%（10/11）。（3）CD105、CD105标记的MVD在浅表性OS中的阳性表达（81.8%、32.51±11.02）明显高于正常对照组（38.9%、22.51±9.53）（P〈0.05）,与普通OS阳性表达率（82.76%）差异无统计学意义（P〉0.05）,但CD105标记的MVD差异有统计学意义（P〈0.05）,而CD105、CD105标记的MVD在浅表性OS及普通OS中的阳性表达与肿瘤大小、性别、年龄无关（P〉0.05）,在普通OS中与转移有关（P〈0.05）。（4）浅表性OS随访2∽7年,10例患者无瘤健在,1例存活74个月（高级别表面OS,49个月后复发为去分化OS）。结论浅表性OS诊断依靠临床、影像学及病理多学科结合,采用传统X线、DR和CT联合检查可提高诊断准确率;浅表性OS中CD105-MVD明显增高,肿瘤性血管生成,参与浅表性OS的发生、发展及影响预后,CD105及CD105-MVD可作为判断生物学行为的参考指标。     

人骨肉瘤中bcl-2的表达与凋亡指数的关系及其临床意义

目的 研究bc1-2蛋白在骨肉瘤中的表达,探讨与凋亡指数（AI）及预后的关系.方法 应用免疫组化方法对34例骨肉瘤组织进行bcl-2蛋白的检测,应用细胞原位凋亡TUNEL技术检测细胞凋亡指数AI,并结合临床资料分析其对预后的影响.结果 34例骨肉瘤中24例bcl-2蛋白（＋）（79.5%）.bcl-2蛋白的表达与骨肉瘤分型无关,但与患者年龄、性别、5年生存状态相关,且与AI有相关性;另外,AI与预后有相关性.结论 bcl-2蛋白、AI可能成为评估骨肉瘤预后的一项重要指标.     

骨肉瘤中肿瘤性骨组织学观察

通过对106例中央型骨肉瘤的肿瘤性骨组织和类骨组织的组织学观察，重点报告了其组织病理学特征和鉴别要点。     

应用血清RANTES诊断严重脓毒症及预后判断的价值评价

目的检测严重脓毒症患者血清中受激活调节正常T细胞表达和分泌因子(RANTES)水平,并评价其对严重脓毒症的诊断和预后价值。方法选取严重脓毒症患者40例为严重脓毒症组(SS组),同期门诊体检者20例为对照组,收集临床及实验室参数,计算APACHEⅡ评分和DIC评分,采用酶联免疫吸附测定(ELISA)方法检测血清RANTES的水平。结果 SS组患者血清RANTES水平[(3 175.91±1 341.78)pg/ml]较对照组[(5 374.27±927.87)pg/ml]下降(P<0.05)。相关分析显示RANTES与WBC、PLT、AST、TBIL、Cr、PT、APTT、PCT、APACHEⅡ评分和DIC评分均呈显著负相关(P<0.05),显示RANTES诊断严重脓毒症的AUCSS=0.917,95%CI 0.817⁰.993(P<0.05),判断严重脓毒症死亡的AUCdeath=0.786,95%CI 0.6500.993(P<0.05),判断严重脓毒症死亡的AUCdeath=0.786,95%CI 0.650⁰.922(P<0.05)。结论严重脓毒症患者的血清RANTES水平明显降低,并死亡率升高,对严重脓毒症的诊断和预后判断有较好的价值。     

富于巨细胞的骨肉瘤1例报道并文献复习

目的探讨富于巨细胞的骨肉瘤的临床、影像学、病理学特点,以提高诊治水平。方法通过影像学、组织学及免疫组织化学对富于巨细胞的骨肉瘤进行观察,总结其特点,并结合文献加以分析。结果富于巨细胞的骨肉瘤呈溶骨性破坏,有大量破骨细胞样巨细胞且分布均匀,与出血无空间关系。背景为成骨性骨肉瘤。免疫组化示破骨细胞样巨细胞、少量组织细胞样单核细胞CD68( ),异型性单核细胞及瘤巨细胞CD68(-);所有细胞vimentin( ),CK、S-100、CD34(-)结论富于巨细胞的骨肉瘤属罕见病例,在影像学、组织学上极易误诊,诊断依赖临床、影像学、病理学三方面的结合。     

microRNA-152在胃癌中表达及与临床病理间关系研究

目的探讨microRNA152（miR152）在胃癌中的表达及其与临床病理特衙间关系。方法采用实时荧光定量PCR法检测70例胃癌组织及其相应癌旁正常组织中miR152表达水平,分析其与患者临床病理指标间关系。结果58例（82．9％）胃癌组织中miR-152表达下调;胃癌组织miR-152表达水平（△CT=5．30±1．47）低于癌旁正常组织（△CT=3．87±1．79）（P〈0．01）;胃癌组织中miR152低表达在肿瘤浸润深度、有无淋巴转移及TNM分期上差异有统计学意义（P〈0．05）。结论miRNA152在胃癌组织中表达明显下调,可促进胃癌发生、发展,可能成为胃癌诊断与治疗的重要生物学标志物。     

胃癌患者血清 microRNA-192和 microRNA-215的表达及临床意义

目的探讨血清miR-192、miR-215作为胃癌诊断标记物的可能性。方法收集2011年9月至2012年1月四川省人民医院29例术前胃癌患者和10名健康对照者血清并提取总RNA,反转录后采用实时荧光定量PCR的方法检测miR-192、miR-215相对表达量,收集胃癌患者的详细临床病理资料,比较miR-192、miR-215在胃癌患者与健康人之间的差异,并与临床病理特征之间的关系进行分析,构建受试者工作特征曲线（ROC曲线）,通过曲线下面积（AUC）计算miR-192、miR-215检测及其联合应用诊断胃癌的敏感性和特异性。结果胃癌患者血清中miR-192、miR-215表达水平分别较正常对照组升高8.87倍（P＝0.002）和4.14倍（P＝0.037）。在不同肿瘤分期、淋巴结转移、肿瘤大小的胃癌患者之间比较,血清中miR-192、miR-215表达无统计学差异。 ROC曲线分析显示,miR-192、miR-215检测及其二者联合应用于胃癌诊断的AUC值分别为0.833（95％CI：0.793～0.993,P＜0.001）、0.724（95％ CI：0.555～0.894,P＝0.002）、0.893（95％CI：0.699～0.966,P＝0.037）,敏感性分别为75.9％、62.1％、75.9％,特异性分别为90.0％、88.3％、92.1％。结论胃癌患者血清中miR-192和miR-215表达可能与胃癌的形成或发展有关。 miR-192、miR-215检测及其联合应用,对胃癌的诊断有较高的敏感性和特异性,提示这两种血清miRNA有望作为胃癌的诊断标记物。     

多层螺旋CT在颌骨骨肉瘤诊断中的价值

目的分析颌骨骨肉瘤多层螺旋CT（MSCT）的影像学特点，探讨MSCT在颌骨骨肉瘤诊断中的价值。方法回顾性分析经手术病理证实的10例颌骨肉瘤的MSCT表现，男3例，女7例，其中2例有鼻咽部放疗史。结果10例骨肉瘤中，发生于下颌骨5例，上颌骨5例，表现为溶骨性骨质破坏3例，成骨改变4例，混合型破坏3例。成骨性骨肉瘤均可见放射状骨膜新生骨，7例见不规则、片状瘤骨，在CT及MRI上软组织肿块均较大。强化明显。MSCT上通过多种不同的后处理方法能够清楚地显示肿瘤术前及术后颌骨的骨质破坏。结论MSCT通过不同的三维重建方法能全方位、直观、详细地显示颌骨骨肉瘤的病灶及其与周围组织结构的关系。     

miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults, however roles of microRNAs (miRNAs) in OS is still unclear. miR-217 is recently widely studied in various cancers, but not including OS. This study is aimed to investigate the expression and cellular function of miR-217 in OS. The data showed that miR-217 expression was consistently lower in OS tissues and cell lines than the normal controls. Restoration of miR-217 expression in MG-63 and U2OS cells could inhibit cell proliferation, migration and invasion, and induced apoptosis. Bioinformatic prediction suggested that Wnt5a is a target gene of miR-217. Using luciferase assay, mRNA and protein expression analysis, it was verified that Wnt5a was a target gene of miR-217 in OS cells. Restored expression of Wnt5a weakened miR-217-mediated suppression of tumor progression. Taken together, our data indicate that miR-217 functions as a tumor suppressor in OS by suppressing Wnt5a expression.     

Association between circulating microRNA-208a and severity of coronary heart disease

Circulating microRNA (miR)-208a is specifically expressed in the heart muscle, which is involved in the regulation of myosin during cardiac development. Previous studies reported that cardiac-specific miR-208a level is significantly higher in plasma of coronary heart disease (CHD) patients. However, whether it correlates with severity of CHD, has never been elucidated before. The aim of this study was to explore the association between miR-208a and the presence and severity of CHD. Samples were collected from 290 CHD patients and 110 subjects with angiographic exclusion of CHD. Circulating miRNA-208a expression was detected using quantitative real-time PCR. The Gensini score was used to evaluate the severity of coronary stenotic lesions. Expression of miRNA-208a was identified on the basis of the quartiles of the Gensini score, and association between the miRNA-208a levels and CHD was analyzed. Diagnostic potential of miR-208a of CHD was performed by ROC analysis. CHD patients had higher miRNA-208a expression (1.61, 0.45–3.86 vs. 0.66, 0.11–1.42, p?p?r?=?0.8525, p?p?相似文献   

ST段抬高型心肌梗死患者循环微RNA-92a表达的研究

目的 了解微RNA-92a(miR-92a)在ST段抬高型心肌梗死(STEMI)发生发展中的表达,以及经皮冠状动脉介入治疗(PCI)对循环miR-92a表达的影响,探讨miR-92a在冠心病临床应用中的可能性.方法 82例STEMI患者及116例慢性稳定型心绞痛(SAP)患者按照是否接受PCI治疗分为STEMI行PCI治疗组(58例)、STEMI未行PCI治疗组(24例)及SAP未行PCI治疗组(116例)3组,分析比较其循环miR-92a表达的差异.结果 STEMI未行PCI患者入院次日循环miR-92a表达水平高于SAP未行PCI者(0.286 9±0.816 7比-0.055 5±0.985 5,P=0.121).PCI治疗24 h后STEMI行PCI患者循环miR-92a表达水平低于STEMI未行PCI者(-0.032 4±0.956 3比0.286 9±0.816 7,P=0.156).SAP未行PCI患者出院存活率显著高于STEMI未行PCI者(100.0％比75.0％,P=0.001),STEMI行PCI患者出院存活率高于STEMI未行PCI者(89.7％比75.0％,P=0.088).结论 STEMI患者循环miR-92a表达增高;PCI治疗能降低STEMI患者循环miR-92a表达;miR-92a表达下调的STEMI患者出院时存活率高于表达上调的STEMI患者.miR-92a很可能具有用于诊断或评估STEMI危险度、提高急性心肌梗死高危患者筛选的敏感性与准确性以及进行干预治疗的临床实际应用价值.